- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Effect of Gefitinib on Brain Metastases From Non-Small Cell Lung Cancer-Two Case Reports-
-
- NISHI Noriyuki
- Department of Neurosurgery, Osaka General Medical Center
-
- KAWAI Shozo
- Department of Neurosurgery, Osaka General Medical Center
-
- YONEZAWA Taiji
- Department of Neurosurgery, Osaka General Medical Center
-
- FUJIMOTO Kenta
- Department of Neurosurgery, Osaka General Medical Center
-
- MASUI Katsuya
- Department of Neurosurgery, Osaka General Medical Center
Bibliographic Information
- Other Title
-
- —Two Case Reports—
Search this article
Description
Two patients with non-small cell lung cancer presented with multiple brain metastases. They received gefitinib orally for the treatment of the primary lung lesions. About one month later, the brain metastases unexpectedly disappeared or became smaller. The patients survived without recurrence of brain metastases and growth of lung lesions for 3-4 years. Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor and is approved for use in the treatment of non-small cell lung cancer. Gefitinib may be very effective for multiple brain metastases in patients with non-small cell lung cancer.<br>
Journal
-
- Neurologia medico-chirurgica
-
Neurologia medico-chirurgica 46 (10), 504-507, 2006
The Japan Neurosurgical Society
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001205054578176
-
- NII Article ID
- 110004849267
-
- NII Book ID
- AN00358613
-
- ISSN
- 13498029
- 04708105
-
- PubMed
- 17062991
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed